Physician profile
Mark Smith
NPI 1396715843
$8,218.26
in general payments reported to CMS, 2019-2025
35 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $707 · 2021: $1,064 · 2022: $1,425 · 2023: $1,366 · 2024: $1,127 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,073.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,330.51 | 2019-2025 | Titan |
| Astellas Pharma US INC | $1,034.64 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $735.63 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $689.80 | 2019-2024 | Xiaflex, Aveed |
| Teleflex LLC | $462.36 | 2022-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $384.02 | 2019-2025 | Axonics, Lithovue |
| Urovant Sciences INC | $379.72 | 2021-2022 | |
| Axonics, INC. | $310.12 | 2023-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $281.09 | 2021-2025 | Interstim |
| Pfizer INC. | $261.85 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.92 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $188.11 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $177.97 | 2019-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $171.50 | 2022-2024 | Prolaris |
| Endo USA, INC. | $148.09 | 2024-2025 | Xiaflex |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $137.78 | 2025 | Cvac Aspiration System |
| Bluewind Medical | $135.54 | 2024 | Revi |
| Antares Pharma, INC. | $133.52 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Procept Biorobotics Corporation | $120.92 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Karl Storz Lithotripsy-America | $114.99 | 2021 | |
| Tolmar, INC. | $110.12 | 2024-2025 | Eligard, Jatenzo |
| Janssen Biotech, INC. | $109.89 | 2019-2024 | Erleada, Akeega, Balversa |
| Olympus America INC. | $85.22 | 2025 | Itind System |
| Dornier Medtech America, INC | $76.34 | 2021 | |
| Abbvie INC. | $65.91 | 2019-2022 | |
| Myovant Sciences INC. | $63.42 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $57.41 | 2023-2025 | Pylarify |
| Urogen Pharma, INC. | $56.26 | 2021-2025 | |
| Allergan, INC. | $54.76 | 2019-2021 | |
| Rochester Medical Corporation | $44.27 | 2021 | |
| Verity Pharmaceuticals INC. | $33.58 | 2023 | Trelstar |
| Halozyme INC | $23.20 | 2023 | |
| Csl Behring | $19.98 | 2020 | |
| Conmed Corporation | $14.60 | 2024 | Airseal |
| Zyla Life Sciences, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.